NCT06908304 2026-01-12A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCMaia BiotechnologyPhase 3 Recruiting300 enrolled
NCT01121393 2018-12-14BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)Boehringer IngelheimPhase 3 Completed364 enrolled 28 charts 1 FDA
NCT00949650 2018-04-06BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationBoehringer IngelheimPhase 3 Completed345 enrolled 23 charts 1 FDA
NCT00404924 2016-09-30ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR FailuresSanofiPhase 3 Completed1,140 enrolled 12 charts
NCT00455936 2010-10-25First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never SmokerNational Cancer Center, KoreaPhase 3 Completed315 enrolled